Septer­na’s $150M in­fu­sion will help prove whether it’s got the right pill for hy­poparathy­roidism

A hefty Se­ries B will bankroll Septer­na’s first clin­i­cal tri­al, which will be a key test of whether the com­pa­ny’s pill will be the first oral op­tion to suc­cess­ful­ly treat hy­poparathy­roidism.

With $150 mil­lion from more than 15 in­vestors, in­clud­ing many mar­quee firms in biotech, Septer­na will study its oral small mol­e­cule in hu­mans and po­ten­tial­ly bring an­oth­er one of its pro­grams in­to the clin­ic, CEO Jef­frey Fin­er told End­points News ahead of Tues­day’s fi­nanc­ing dis­clo­sure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER